DBV Technologies S.A. American Depositary Shares, also called DBV Technologies, is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. Read More It focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France. The listed name for DBVT is DBV Technologies S.A. American Depositary Shares.